dpp-4 inhibitor with glp-1 receptor agonist combination not recommended ada Development of a treatment selection algorithm for SGLT2 and therapies in people type 2 diabetes: a retrospective cohort study Molecular Insights into the Potential
Description
Diabetologia 2008
LaubySecretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K
Glucagonlike peptide 1 receptor agonists and risk of thyroid cancer: an international multisite cohort study
The DPP-4 inhibitors prolong the action of endogenous incretins, enhancing the first-phase insulin response
Writing original draft
